Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.48 |
| ▸ | RARB | P10826 | 4/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM6B | O15054 | 1/20 | 0.47 |
| ▸ | TET3 | O43151 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | KDM5C | P41229 | 1/20 | 0.47 |
| ▸ | ASPH | Q12797 | 1/20 | 0.47 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.47 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10986249 | 0.94 | PLA2G2A (0.56) | TP53TSHRPLA2G4BPTPN11RARB | |
| SCHEMBL4069028 | 0.92 | ALPL (0.46) | TP53TSHRPLA2G4BPTPN11RARB | |
| SCHEMBL4078541 | 0.90 | TP53 (0.43) | TP53TSHRPLA2G4BPTPN11RARB | |
| SCHEMBL27639521 | 0.85 | KDM4E (0.52) | TP53TSHRPLA2G4BKDM4EALDH1A1 | |
| SCHEMBL15956090 | 0.84 | TSHR (0.50) | TP53TSHRCYP3A4CYP2D6KDM4E | |
| SCHEMBL2454478 | 0.84 | ALPL (0.50) | TSHRPLA2G2ACYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL4134527 | 0.84 | KDM4E (0.45) | RARBKDM4EALDH1A1KDM6BTET3 | |
| SCHEMBL10098352 | 0.84 | KDM4E (0.47) | KDM4EALDH1A1KDM6BTET3KDM4A | |
| SCHEMBL4224095 | 0.83 | RARB (0.66) | TP53TSHRPLA2G4BPTPN11RARB | |
| SCHEMBL19486623 | 0.79 | CYP2D6 (0.46) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508484-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3342771-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| EP-3375780-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| US-20190262356-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-29 | — | — | US | disclosed |
| EP-3508484-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-07-10 | — | — | EP | disclosed |
| US-20190201413-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-10292987-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| EP-3342771-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2018-07-04 | — | — | EP | disclosed |
| CN-1315859-C | Lincomycin derivatives possessing antibacterial activity | VICURON PHARM INC (US) | 2007-05-16 | — | — | CN | disclosed |
| US-7199105-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7164011-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1654268-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| CN-1681832-A | Lincomycin derivatives possessing antibacterial activity | VICURON PHARM INC (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1529052-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2005007665-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-11-18 | — | — | US | disclosed |
| US-20040116690-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004016632-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | NRDC, NISCH, CLSPN | TP53 4710/4885TSHR 3561/4885PLA2G4B 2272/4885 |
| US-20190201413-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | TP53 1028/4885TSHR 741/4885PLA2G4B 1864/4885 |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | TP53 1028/4885TSHR 741/4885PLA2G4B 1864/4885 |
| US-20190262356-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | TP53 1028/4885TSHR 741/4885PLA2G4B 1864/4885 |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | TP53 1028/4885TSHR 741/4885PLA2G4B 1864/4885 |
| US-10292987-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | TP53 1028/4885TSHR 741/4885PLA2G4B 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.